Publications by authors named "Murciano-Anton M"
Article Synopsis
- After mild COVID-19, some individuals develop a condition called Post-COVID condition (PCC) characterized by lingering symptoms and persistent immune system changes.
- A study compared the immune responses of people with PCC to those with mild, severe, and critical COVID-19, focusing on specific CD4+ T helper cell types.
- Results indicated that people with PCC had a unique immune profile, including low Th1 cells, high Th2 response, and elevated pro-inflammatory Th9 and Th17 cells, which may hinder the body's ability to fight off infections and contribute to prolonged symptoms.
Article Synopsis
- * Dasatinib, a medication used for chronic myeloid leukemia, shows promise against HIV-1 by preserving the antiviral activity of the SAMHD1 protein in CD4+ T cells and reducing the phosphorylation that inactivates it, inhibiting HIV-1 infection in macrophages.
- * Short-term dasatinib treatment lowers inflammatory cytokines in macrophages while maintaining some antiviral responses, suggesting that combining dasatinib with ART could effectively target HIV-1 reservoirs and reduce inflammation in people living with HIV.
Introduction: HIV-1 infection may produce a detrimental effect on the immune response. Early start of antiretroviral therapy (ART) is recommended to preserve the integrity of the immune system. In fact, people with HIV (PWH) and normal CD4/CD8 ratio appear not to be more susceptible to severe forms of COVID-19 than the general population and they usually present a good seroconversion rate in response to vaccination against SARS-CoV-2.
View Article and Find Full Text PDFArticle Synopsis
- * A study focused on 29 CML patients, some on TKIs and others in treatment-free remission, comparing their immune responses after full COVID-19 vaccination with 20 healthy individuals over 17 months.
- * Results showed that while CML patients developed a strong immune response similar to healthy individuals, their antibody-dependent cytotoxic activity was reduced, leading to slightly higher rates of mild COVID-19 breakthrough infections, particularly in those avoiding treatment.
Article Synopsis
- - The study focuses on the effectiveness of COVID-19 vaccination in individuals with oncohematological diseases (OHD) who received hematopoietic stem cell transplants (HSCT), addressing significant morbidity and mortality rates prior to vaccination.
- - It was found that these individuals maintained low but protective levels of neutralizing antibodies against SARS-CoV-2 after undergoing HSCT, indicating some persistent immune protection despite B-cell deficiencies.
- - Results showed that although cellular immunity was impaired in those who had allogeneic HSCT, infections that occurred post-transplant were mild, reinforcing the necessity and safety of COVID-19 vaccination for this vulnerable group.
Strong Humoral but Not Cellular Immune Responses against SARS-CoV-2 in Individuals with Oncohematological Disease Who Were Treated with Rituximab before Receiving a Vaccine Booster.
Cancers (Basel)
November 2022
The humoral immune response developed after receiving the full vaccination schedule against COVID-19 is impaired in individuals who received anti-CD20 therapy 6-9 months before vaccination. However, there is little information about the cellular immune responses elicited in these individuals. In this study, we analyzed the humoral and cellular immune responses in 18 individuals with hematological disease who received the last dose of rituximab 13.
View Article and Find Full Text PDFThe clinical presentations of COVID-19 may range from an asymptomatic or mild infection to a critical or fatal disease. Several host factors such as elderly age, male gender, and previous comorbidities seem to be involved in the most severe outcomes, but also an impaired immune response that causes a hyperinflammatory state but is unable to clear the infection. In order to get further understanding about this impaired immune response, we aimed to determine the association of specific HLA alleles with different clinical presentations of COVID-19.
View Article and Find Full Text PDFIndividuals with oncohematological diseases (OHD) may develop an impaired immune response against vaccines due to the characteristics of the disease or to its treatment. Humoral response against SARS-CoV-2 has been described to be suboptimal in these patients, but the quality and efficiency of the cellular immune response has not been yet completely characterized. In this study, we analyzed the early humoral and cellular immune responses in individuals with different OHD after receiving one dose of an authorized vaccine against SARS-CoV-2.
View Article and Find Full Text PDFOncohematological patients show a low immune response against SARS-CoV-2, both to natural infection and after vaccination. Most studies are focused on the analysis of the humoral response; therefore, the information available about the cellular immune response is limited. In this study, we analyzed the humoral and cellular immune responses in nine individuals who received chemotherapy for their oncohematological diseases, as well as consolidation with autologous stem cell transplantation (ASCT), after being naturally infected with SARS-CoV-2.
View Article and Find Full Text PDFArticle Synopsis
- Long-COVID is a new syndrome marked by symptoms lingering for over four weeks after a COVID-19 infection, with potential causes still being researched.
- A study on Spanish individuals found that those with Long-COVID had significantly higher levels of certain immune cells, indicating a strong antiviral response.
- By analyzing clinical symptoms and demographic factors, researchers developed a Random Forest algorithm that accurately predicted Long-COVID status, suggesting that identifying specific biomarkers could enhance patient management.
SARS-CoV-2 infection causes COVID-19, ranging from mild to critical disease in symptomatic subjects. It is essential to better understand the immunologic responses occurring in patients with the most severe outcomes. In this study, parameters related to the humoral immune response elicited against SARS-CoV-2 were analysed in 61 patients with different presentations of COVID-19 who were recruited in Hospitals and Primary Healthcare Centres in Madrid, Spain, during the first pandemic peak between April and June 2020.
View Article and Find Full Text PDFArticle Synopsis
- Infection with the novel coronavirus SARS-CoV-2 can lead to various forms of COVID-19, with some patients progressing to critical stages requiring ICU care and mechanical ventilation.
- This study analyzed immune response parameters in blood samples from 109 COVID-19 patients to identify biomarkers that could predict who might develop severe disease.
- Findings showed that patients with severe COVID-19 had a strong inflammatory response but poor immune function, highlighting the need to improve cytotoxic responses against the virus while managing excessive inflammation.
Objective: Meniscus injury is one of the causes of secondary osteoarthritis (OA). However, the role of meniscus is still unclear. Human meniscal distribution of cells and cartilage oligomeric matrix protein (COMP) and their changes in advanced OA were analyzed.
View Article and Find Full Text PDFBackground: Knee osteoarthritis mainly affecting the lateral facet of the patella, especially in young patients, is a definite challenge to the surgeon. Our purpose was to investigate the long-term outcome of a simple operation such as the partial lateral facetectomy on middle-aged to elderly patients with predominant lateral patellofemoral osteoarthritis.
Methods: A retrospective, long-term study of 39 knees (28 females, mean aged at surgery 61yearsold) with a minimum follow-up of 10years was performed.
Introduction: Secondary knee osteoarthritis (OA) is currently associated with meniscal injuries, but the pathogenesis is unclear. We analyzed the distribution of cells and cartilage oligomeric matrix protein (COMP) and its changes in the early stages of degeneration in meniscus.
Method: Ten New Zealand rabbits underwent anterior cruciate ligament (ACL)-transection of the right knee-joint.